What is CAPR's current stock price?

CAPR (Capricor Therapeutics, Inc.) is currently trading at $28.87 with a market cap of $1.32B.

What sector is Capricor Therapeutics, Inc. in?

Capricor Therapeutics, Inc. (CAPR) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CAPR a good stock to buy?

Analysts have a Buy consensus on CAPR with a price target of $50.88. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CAPR Capricor Therapeutics, Inc.

Healthcare

$28.87-2.40%ClosedMarket Cap: $1.32B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

5.95

P/S

0.00

EV/EBITDA

-10.54

DCF Value

$5.71

FCF Yield

-8.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-59.3%

ROA

-35.1%

ROIC

-40.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-33.9M	$—
Q4 null	$0.00	$-30.2M	$—
FY null	$0.00	$-105.0M	$—
Q3 null	$0.00	$-24.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$50.88

Target (Median)

$50.00

Target Range

$38.00 - $62.00

2 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-13

B. Riley SecuritiesBuy

2026-03-13

HC Wainwright & Co.Buy

2026-03-13

Piper SandlerOverweight

2026-03-13

B. Riley SecuritiesBuy

2025-12-15

Trading Activity

Insider Trades

View All

Bergmann Anthonyofficer: CHIEF FINANCIAL OFFICER

SellTue May 19

Litvack Frankdirector

SellThu May 14

Krasney Karenofficer: EVP, GENERAL COUNSEL

SellMon May 04

Krasney Karenofficer: EVP, GENERAL COUNSEL

SellMon May 04

Bergmann Anthonyofficer: CHIEF FINANCIAL OFFICER

SellMon May 04

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.48

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Peers